Overview
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
Status:
NOT_YET_RECRUITING
NOT_YET_RECRUITING
Trial end date:
2028-12-31
2028-12-31
Target enrollment:
Participant gender: